Screener
Neurocrine Biosciences NBIX EV / EBITDA
EV / EBITDA at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on the most recent quarter.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
FAQ
- What is Neurocrine Biosciences's EV / EBITDA?
- Neurocrine Biosciences (NBIX) reported EV / EBITDA of 16.4× in Q1 2026.
- How has Neurocrine Biosciences's EV / EBITDA changed year-over-year?
- Neurocrine Biosciences's EV / EBITDA decreased by 24.3% year-over-year, from 21.6× to 16.4×.
- What is the long-term trend for Neurocrine Biosciences's EV / EBITDA?
- Over 4 years (2020 to 2025), Neurocrine Biosciences's EV / EBITDA has grown at a -20.1% compound annual growth rate (CAGR), from 52.5× to 21.4×.
- What does EV / EBITDA mean?
- Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.
Ask your AI about Neurocrine Biosciences's ev / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude